MLANA and neoplasm: MART‐1 protein‐expressing SK‐MEL‐5 (Figure 4A, p > 0.05) and Malme‐3M (Figure 4C, p > 0.05) tumor cells were sensitive to MART‐1‐specific CD8+ T cell cytolytic activity, regardless of the presence of the P26‐35 peptide.